Literature DB >> 7506185

Oral challenge with alternative nonsteroidal antiinflammatory drugs (NSAIDs) and paracetamol in patients intolerant to these agents.

M Ispano1, A Fontana, J Scibilia, C Ortolani.   

Abstract

The reliability and safety of the oral challenge procedure were evaluated in the diagnosis and prevention of intolerance to nonsteroidal anti-inflammatory drugs (NSAIDs). 112 NSAID-intolerant patients were submitted to oral challenge with aspirin (acetylsalicylic acid), dipyrone, paracetamol, imidazole-hydroxybenzoate or nimesulide to confirm historic intolerance and to evaluate tolerance to other NSAIDs. A significant correlation was demonstrated between history of intolerance and the results of oral challenge in aspirin-intolerant patients (p < 0.001). Of 237 challenges with various NSAIDs and paracetamol in 101 patients, 19 challenges were positive and 2 patients developed anaphylactic shock. The ratio of positive: total challenges with alternative NSAIDs and paracetamol were as follows: 7 of 83 for paracetamol, 2 of 49 for imidazole-hydroxybenzoate and 0 of 30 for nimesulide. On the basis of these results, nimesulide was evaluated as an alternative NSAID in a second group of 284 NSAID-intolerant patients. Challenge with nimesulide elicited a positive response in 14 patients (in 6 patients the response was delayed), although adverse reactions were mild in all instances. In conclusion, a positive history of intolerance to a given NSAID is a sufficient reason to contraindicate its use even for diagnostic purposes, e.g. oral challenge. Oral challenge should therefore be restricted to the assessment of the tolerability of alternative NSAIDs. In the present study nimesulide appeared to be the safest currently available alternative in patients with NSAID intolerance.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7506185     DOI: 10.2165/00003495-199300461-00065

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  5 in total

1.  Clinical patterns of hypersensitivity to nonsteroidal anti-inflammatory drugs and their pathogenesis.

Authors:  A Szczeklik; R J Gryglewski; G Czerniawska-Mysik
Journal:  J Allergy Clin Immunol       Date:  1977-11       Impact factor: 10.793

2.  Intolerance to aspirin. Clinical studies and consideration of its pathogenesis.

Authors:  M Samter; R F Beers
Journal:  Ann Intern Med       Date:  1968-05       Impact factor: 25.391

Review 3.  Adverse reactions to aspirin and nonsteroidal anti-inflammatory drugs.

Authors:  A Szczeklik
Journal:  Ann Allergy       Date:  1987-11

4.  Diagnosis, prevention, and treatment of adverse reactions to aspirin and nonsteroidal anti-inflammatory drugs.

Authors:  D D Stevenson
Journal:  J Allergy Clin Immunol       Date:  1984-10       Impact factor: 10.793

5.  Aspirin and concomitant idiosyncrasies in adult asthmatic patients.

Authors:  S L Spector; C H Wangaard; R S Farr
Journal:  J Allergy Clin Immunol       Date:  1979-12       Impact factor: 10.793

  5 in total
  5 in total

Review 1.  The importance of COX-2 inhibition for aspirin induced asthma.

Authors:  A Bennett
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

Review 2.  Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice.

Authors:  Christine Jenkins; John Costello; Linda Hodge
Journal:  BMJ       Date:  2004-02-21

3.  Clinical management of adult patients with a history of nonsteroidal anti-inflammatory drug-induced urticaria/angioedema: update.

Authors:  Riccardo Asero
Journal:  Allergy Asthma Clin Immunol       Date:  2007-03-15       Impact factor: 3.406

Review 4.  Nimesulide in the treatment of patients intolerant of aspirin and other NSAIDs.

Authors:  G E Senna; G Passalacqua; G Andri; A R Dama; M Albano; L Fregonese; L Andri
Journal:  Drug Saf       Date:  1996-02       Impact factor: 5.606

Review 5.  Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  R Davis; R N Brogden
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.